Association of lower tumor mutation burden with rapid local progression in patients with brain metastases.

doi:10.3171/2024.9.JNS241391

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Association of lower tumor mutation burden with rapid local progression in patients with brain metastases.

Journal of neurosurgery - 1 Jun 2025

Shukla Poojan D, Nguyen Minh P, Lui Austin, Catalan Tony, Young Jacob S, Berger Mitchel S, Theodosopoulos Philip V, Hervey-Jumper Shawn L, Huppert Laura A, Aghi Manish K, Vasudevan Harish N, Morshed Ramin A

Abstract excerpt

OBJECTIVE: Tumor mutational burden (TMB) has been proposed as a prognostic biomarker in patients with metastatic cancer, as well as in patients who receive immune checkpoint inhibitor (ICI) therapy. However, the role of TMB as a biomarker for progression after resection of brain metastases, as well as perioperative ICI treatment response, is less defined. This study examined the impact of TMB on local CNS...

Read the complete abstract on PubMed

Topics

Humans
Brain Neoplasms
Male
Female
Middle Aged
Retrospective Studies

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Disease Progression

Mutation

Aged

Adult

Biomarkers, Tumor

Immune Checkpoint Inhibitors

Cohort Studies

Tumor Burden

Aged, 80 and over

Source

Open in PubMed

Identifiers

PMID: 39951711
DOI: 10.3171/2024.9.JNS241391

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 28 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association of lower tumor mutation burden with rapid local progression in patients with brain metastases.PMID 39951711Read ↗

A Systematic Review and Meta-Analysis of the Impact of Tumour Mutation Burden on Survival Outcomes in Solid Tumours.Semantic proximity Read ↗

Sequencing brain metastases and opportunities for targeted therapies.Semantic proximity Read ↗

Genomics correlates of brain metastasis and progression in colorectal cancer.Semantic proximity Read ↗

A Systematic Review and Meta-Analysis of the Impact of Tumour Mutation Burden on Survival Outcomes in Solid TumoursSemantic proximity Read ↗

Tumor mutational burden as a prognostic biomarker for survival and quality of life in metastatic colorectal cancer patients receiving anti-PD-1/PD-L1 immunotherapy: A retrospective cohort study.Semantic proximity Read ↗

Assessment of Tumor Mutational Burden and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy.Semantic proximity Read ↗

Treatment of brain metastases in the modern genomic era.Semantic proximity Read ↗

Outcomes and Molecular Features of Brain Metastasis in Gastroesophageal Adenocarcinoma.Semantic proximity Read ↗

Interplay between Tumor Mutational Burden and Mutational Profile and its effect on overall survival: A Post Hoc Analysis of Metastatic Patients Treated with Immune Checkpoint InhibitorsSemantic proximity Read ↗

Tumor mutational burden as a determinant of metastatic dissemination patterns.Semantic proximity Read ↗

Molecular Profiles of Brain Metastases: A Focus on HeterogeneitySemantic proximity Read ↗

Genomic profiling of brain metastases: current knowledge and new frontiers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.